Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.

Literature DB >> 30385523

Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.

Rachel Schiff^1,2,3, Rinath Jeselsohn^4,5,6.

Abstract

The correlative circulating tumor DNA (ctDNA) studies of the PALOMA-3 clinical trial showed that acquired resistance to fulvestrant and palbociclib is associated with clonal evolution and acquired mutations in RB1, PIK3CA, and ESR1, with the latter two related to fulvestrant resistance. These results highlight the potential of ctDNA as a tool to detect mechanisms of resistance and infer the next line of treatment. Cancer Discov; 8(11); 1352-4. ©2018 AACR See related article by O'Leary et al., p. 1390. ©2018 American Association for Cancer Research.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2018 PMID： 30385523 PMCID： PMC6217858 DOI： 10.1158/2159-8290.CD-18-1084

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

11 in total

1. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Authors: Rinath Jeselsohn; Johann S Bergholz; Matthew Pun; MacIntosh Cornwell; Weihan Liu; Agostina Nardone; Tengfei Xiao; Wei Li; Xintao Qiu; Gilles Buchwalter; Ariel Feiglin; Kayley Abell-Hart; Teng Fei; Prakash Rao; Henry Long; Nicholas Kwiatkowski; Tinghu Zhang; Nathanael Gray; Diane Melchers; Rene Houtman; X Shirley Liu; Ofir Cohen; Nikhil Wagle; Eric P Winer; Jean Zhao; Myles Brown
Journal: Cancer Cell Date: 2018-02-12 Impact factor: 31.743

2. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.

Authors: Jérôme Eeckhoute; Jason S Carroll; Timothy R Geistlinger; Maria I Torres-Arzayus; Myles Brown
Journal: Genes Dev Date: 2006-09-15 Impact factor: 11.361

3. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis.

Authors: Rinath Jeselsohn; Nelson E Brown; Lisa Arendt; Ina Klebba; Miaofen G Hu; Charlotte Kuperwasser; Philip W Hinds
Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743

4. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors: Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466

5. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors: Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal: Lancet Oncol Date: 2016-03-03 Impact factor: 41.316

Review 6. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.

Authors: Carmen Criscitiello; Giulia Viale; Giuseppe Curigliano; Aron Goldhirsch
Journal: Breast Cancer (Dove Med Press) Date: 2018-01-30

7. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

Authors: Ben O'Leary; Sarah Hrebien; James P Morden; Matthew Beaney; Charlotte Fribbens; Xin Huang; Yuan Liu; Cynthia Huang Bartlett; Maria Koehler; Massimo Cristofanilli; Isaac Garcia-Murillas; Judith M Bliss; Nicholas C Turner
Journal: Nat Commun Date: 2018-03-01 Impact factor: 14.919

8. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Authors: Charlotte Fribbens; Ben O'Leary; Lucy Kilburn; Sarah Hrebien; Isaac Garcia-Murillas; Matthew Beaney; Massimo Cristofanilli; Fabrice Andre; Sherene Loi; Sibylle Loibl; John Jiang; Cynthia Huang Bartlett; Maria Koehler; Mitch Dowsett; Judith M Bliss; Stephen R D Johnston; Nicholas C Turner
Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544